Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
14.46
0.00 (0.00%)
At close: Apr 14, 2026, 4:00 PM EDT
14.45
-0.01 (-0.07%)
After-hours: Apr 14, 2026, 7:05 PM EDT
Amicus Therapeutics Market Cap
Amicus Therapeutics has a market cap or net worth of $4.54 billion as of April 14, 2026. Its market cap has increased by 76.06% in one year.
Market Cap
4.54B
Enterprise Value
4.69B
1-Year Change
76.06%
Ranking
Category
Stock Price
$14.46
Market Cap Chart
Since May 31, 2007, Amicus Therapeutics's market cap has increased from $320.80M to $4.54B, an increase of 1,314.86%. That is a compound annual growth rate of 15.06%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 13, 2026 | 4.54B | 3.35% |
| Dec 31, 2025 | 4.39B | 56.09% |
| Dec 31, 2024 | 2.81B | -32.36% |
| Dec 29, 2023 | 4.16B | 21.31% |
| Dec 30, 2022 | 3.43B | 6.59% |
| Dec 31, 2021 | 3.22B | -46.51% |
| Dec 31, 2020 | 6.02B | 142.45% |
| Dec 31, 2019 | 2.48B | 36.86% |
| Dec 31, 2018 | 1.81B | -24.21% |
| Dec 29, 2017 | 2.39B | 238.22% |
| Dec 30, 2016 | 707.40M | -41.61% |
| Dec 31, 2015 | 1.21B | 83.56% |
| Dec 31, 2014 | 660.00M | 466.04% |
| Dec 31, 2013 | 116.60M | -12.00% |
| Dec 31, 2012 | 132.50M | 11.16% |
| Dec 30, 2011 | 119.20M | -8.24% |
| Dec 31, 2010 | 129.90M | 44.49% |
| Dec 31, 2009 | 89.90M | -50.11% |
| Dec 31, 2008 | 180.20M | -25.01% |
| Dec 31, 2007 | 240.30M | -25.09% |
| May 31, 2007 | 320.80M | - |
View and export this data all the way back to 2007. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Apellis Pharmaceuticals | 5.22B |
| Immunovant | 5.11B |
| Erasca | 5.07B |
| TG Therapeutics | 4.99B |
| Spyre Therapeutics | 4.97B |
| Dianthus Therapeutics | 4.76B |
| Corcept Therapeutics | 4.61B |
| Ligand Pharmaceuticals | 4.26B |